Comparative effects of carrier proteins on vaccine-induced immune response

Vaccine

Volumn 29, Issue 31, 2011, Pages 4881-4890

  Knuf, Markus ^a,b   Kowalzik, Frank ^b   Kieninger, Dorothee ^b  

^a DR HORST SCHMIDT KLINIKEN   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Carrier proteins; Conjugate chemistry; Conjugate vaccine; CRM197 conjugate; Quadrivalent vaccine

Indexed keywords

ANTIBODY; CARRIER PROTEIN; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TOXOID; HAEMOPHILUS INFLUENZAE DERIVED PROTEIN D; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; MEASLES MUMPS RUBELLA VACCINE; MENINGOCOCCUS VACCINE; ORAL POLIOMYELITIS VACCINE; OUTER MEMBRANE PROTEIN; PEDIACEL; PNEUMOCOCCUS VACCINE; TETANUS TOXOID; UNCLASSIFIED DRUG; VAXEMHIB;

ADAPTIVE IMMUNITY; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANTIBODY TITER; BRONCHOSPASM; COMPARATIVE EFFECTIVENESS; DIPHTHERIA; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG SAFETY; FACE EDEMA; FEBRILE CONVULSION; HAEMOPHILUS INFECTION; HEPATITIS B; HUMAN; HYPOTENSION; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE ABSCESS; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; LYMPHADENOPATHY; MENINGOCOCCOSIS; PERTUSSIS; PNEUMOCOCCAL INFECTION; POLIOMYELITIS; PRIORITY JOURNAL; REVIEW; SERUM BACTERICIDAL ANTIBODY ASSAY; SKIN REDNESS; SYNCOPE; TETANUS; URTICARIA;

ADJUVANTS, IMMUNOLOGIC; CARRIER PROTEINS; HAEMOPHILUS VACCINES; HUMANS; MENINGOCOCCAL VACCINES; PNEUMOCOCCAL VACCINES; POLYSACCHARIDES, BACTERIAL; VACCINES, CONJUGATE;

EID: 79959686712     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.04.053     Document Type: Review

References (53)

1. Harrison L.H. Prospects for vaccine prevention of meningococcal infection. Clin Microbiol Rev 2006, 19(January (1)):142-164.
2. Broker M., Dull P.M., Rappuoli R., Costantino P. Chemistry of a new investigational quadrivalent meningococcal conjugate vaccine that is immunogenic at all ages. Vaccine 2009, 27(September (41)):5574-5580.
3. Pollabauer E.M., Petermann R., Ehrlich H.J. The influence of carrier protein on the immunogenicity of simultaneously administered conjugate vaccines in infants. Vaccine 2009, 27(March (11)):1674-1679.
4. Kelly D.F., Moxon E.R., Pollard A.J. Haemophilus influenzae type b conjugate vaccines. Immunology 2004, 113(October (2)):163-174.
5. ACTHib [package insert]. Swiftwater, PA: Sanofi Pasteur; 2005.
6. Menactra [package insert]. Swiftwater, PA: Sanofi Pasteur; 2009.
7. PedvaxHIB [package insert]. West Point, PA: Merck and Co., Inc.; 2001.
8. Forsgren A., Riesbeck K., Janson H. Protein D of Haemophilus influenzae: a protective nontypeable H. influenzae antigen and a carrier for pneumococcal conjugate vaccines. Clin Infect Dis 2008, 46(March (5)):726-731.
9. Rappuoli R. Isolation and characterization of Corynebacterium diphtheriae nontandem double lysogens hyperproducing CRM197. Appl Environ Microbiol 1983, 46(3):560-564.
10. Uchida T., Pappenheimer A.M., Harper A.A. Reconstitution of diphtheria toxin from two nontoxic cross-reacting mutant proteins. Science 1972, 175(February (24)):901-903.
11. Holmes M.J., Ryan W.L. Amino acid analysis and molecular weight determination of tetanus toxin. Infect Immun 1971, 3(January (1)):133-140.
12. Liu M.A., Friedman A., Oliff A.I., Tai J., Martinez D., Deck R.R., et al. A vaccine carrier derived from Neisseria meningitidis with mitogenic activity for lymphocytes. Proc Natl Acad Sci USA 1992, 89(May (10)):4633-4637.
13. Decker M.D., Edwards K.M., Bradley R., Palmer P. Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines. J Pediatr 1992, 120(February (2 Pt 1)):184-189.
14. Hiberix [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2009.
15. Menitorix [summary of product characteristics]. Uxbridge, United Kingdom: GlaxoSmithKline; 2009.
16. NeisVac-C [product monograph]. Mississauga, Canada: GlaxoSmithKline Inc.; 2009.
17. Jackson L.A., Baxter R., Reisinger K., Karsten A., Shah J., Bedell L., et al. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents. Clin Infect Dis 2009, 49(July (1)):e1-e10.
18. Knuf M., Kieninger-Baum D., Habermehl P., Muttonen P., Maurer H., Vink P., et al. A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children. Vaccine 2010, 28(January (3)):744-753.
19. Meningitec [product monograph]. Quebec, Canada: Wyeth; 2007.
20. Menjugate [summary of product characteristics]. Sienna, Italy: Novartis Vaccines and Diagnostics; 2009.
21. Prevnar [package insert]. Philadelphia, PA; Wyeth Pharmaceuticals; 2009.
22. Vaxem Hib [summary of product characteristics]. Sienna, Italy: Novartis Vaccines and Diagnostics; 2007.
23. MacLennan J.M., Shackley F., Heath P.T., Deeks J.J., Flamank C., Herbert M., et al. Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: a randomized controlled trial. JAMA 2000, 283(June (21)):2795-2801.
24. Prevnar 13 [package insert]. Philadelphia, PA; Wyeth Pharmaceuticals; 2010.
25. Snape M.D., Kelly D.F., Lewis S., Banner C., Kibwana L., Moore C.E., et al. Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study. BMJ 2008, 336(June (7659)):1487-1491.
26. Snape M.D., Perrett K.P., Ford K.J., John T.M., Pace D., Yu L.M., et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA 2008, 299(January (2)):173-184.
27. Southern J., Borrow R., Andrews N., Morris R., Waight P., Hudson M., et al. Immunogenicity of a reduced schedule of meningococcal group C conjugate vaccine given concomitantly with the Prevenar and Pediacel vaccines in healthy infants in the United Kingdom. Clin Vaccine Immunol 2009, 16(February (2)):194-199.
28. Richmond P., Borrow R., Goldblatt D., Findlow J., Martin S., Morris R., et al. Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J Infect Dis 2001, 183(January (1)):160-163.
29. Menveo [package insert]. Cambridge, MA: Novartis Vaccines and Diagnostics; 2010.
30. Pace D., Pollard A.J., Messonier N.E. Quadrivalent meningococcal conjugate vaccines. Vaccine 2009, 27(June (Suppl. 2)):B30-B41.
31. Perrett K.P., Snape M.D., Ford K.J., John T.M., Yu L.M., Langley J.M., et al. Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants. Pediatr Infect Dis Z J 2009, 28(March (3)):186-193.
32. Rennels M., King J., Ryall R., Papa T., Froeschle J. Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine in infants. Pediatr Infect Dis J 2004, 23(May (5)):429-435.
33. Granoff D.M. Review of meningococcal group B vaccines. Clin Infect Dis 2010, 50(March (Suppl. 2)):S54-S65.
34. Dagan R., Poolman J.T., Zepp F. Combination vaccines containing DTPa-Hib: impact of IPV and coadministration of CRM197 conjugates. Expert Rev Vaccines 2008, 7(February (1)):97-115.
35. Granoff D.M., Anderson E.L., Osterholm M.T., Holmes S.J., McHugh J.E., Belshe R.B., et al. Differences in the immunogenicity of three Haemophilus influenzae type b conjugate vaccines in infants. J Pediatr 1992, 121(August (2)):187-194.
36. Lee H., Hahn S., Lee H.J., Kim K.H. Immunogenicity of Haemophilus influenzae type b conjugate vaccines in Korean infants: a meta-analysis. J Korean Med Sci 2010, 25(January (1)):90-96.
37. Black S., Shinefield H., Fireman B., Lewis E., Ray P., Hansen J.R., et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000, 19(March (3)):187-195.
38. Prymula R., Peeters P., Chrobok V., Kriz P., Novakova E., Kaliskova E., et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 2006, 367(March (9512)):740-748.
39. Dagan R., Melamed R., Zamir O., Leroy O. Safety and immunogenicity of tetravalent pneumococcal vaccines containing 6B, 14, 19F and 23F polysaccharides conjugated to either tetanus toxoid or diphtheria toxoid in young infants and their boosterability by native polysaccharide antigens. Pediatr Infect Dis J 1997, 16(November (11)):1053-1059.
40. Shinefield H.R. Overview of the development and current use of CRM(197) conjugate vaccines for pediatric use. Vaccine 2010, 28(June (27)):4335-4339.
41. Dagan R., Poolman J., Siegrist C.A. Glycoconjugate vaccines and immune interference: a review. Vaccine 2010, 28(August (34)):5513-5523.
42. Dagan R., Eskola J., Leclerc C., Leroy O. Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants. Infect Immun 1998, 66(May (5)):2093-2098.
43. Dagan R., Goldblatt D., Maleckar J.R., Yaich M., Eskola J. Reduction of antibody response to an 11-valent pneumococcal vaccine coadministered with a vaccine containing acellular pertussis components. Infect Immun 2004, 72(September (9)):5383-5391.
44. Kitchin N.R., Southern J., Morris R., Hemme F., Thomas S., Watson M.W., et al. Evaluation of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b vaccine given concurrently with meningococcal group C conjugate vaccine at 2, 3 and 4 months of age. Arch Dis Child 2007, 92(January (1)):11-16.
45. Southern J., Crowley-Luke A., Borrow R., Andrews N., Miller E. Immunogenicity of one, two or three doses of a meningococcal C conjugate vaccine conjugated to tetanus toxoid, given as a three-dose primary vaccination course in UK infants at 2, 3 and 4 months of age with acellular pertussis-containing DTP/Hib vaccine. Vaccine 2006, 24(January (2)):215-219.
46. Schmitt H.J., Maechler G., Habermehl P., Knuf M., Saenger R., Begg N., et al. Immunogenicity, reactogenicity, and immune memory after primary vaccination with a novel Haemophilus influenzae-Neisseria meningitidis serogroup C conjugate vaccine. Clin Vaccine Immunol 2007, 14(April (4)):426-434.
47. Usonis V., Bakasenas V., Lockhart S., Baker S., Gruber W., Laudat F. A clinical trial examining the effect of increased total CRM(197) carrier protein dose on the antibody response to Haemophilus influenzae type b CRM(197) conjugate vaccine. Vaccine 2008, 26(August (35)):4602-4607.
48. Buttery J.P., Riddell A., McVernon J., Chantler T., Lane L., Bowen-Morris J., et al. Immunogenicity and safety of a combination pneumococcal-meningococcal vaccine in infants: a randomized controlled trial. JAMA 2005, 293(April (14)):1751-1758.
49. Knuf M., Szenborn L., Moro M., Petit C., Bermal N., Bernard L., et al. Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV). Pediatr Infect Dis J 2009, 28(April (4 Suppl.)):S97-S108.
50. Ward J., Brenneman G., Letson G.W., Heyward W.L. Limited efficacy of a Haemophilus influenzae type b conjugate vaccine in Alaska Native infants. The Alaska H. influenzae Vaccine Study Group. N Engl J Med 1990, 323(November (20)):1393-1401.
51. Black S.B., Shinefield H.R., Fireman B., Hiatt R., Polen M., Vittinghoff E. Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61,080 children. The Northern California Kaiser Permanente Vaccine Study Center Pediatrics Group. Pediatr Infect Dis J 1991, 10(February (2)):97-104.
52. Peltola H., Makela H., Kayhty H., Jousimies H., Herva E., Hallstrom K., et al. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. N Engl J Med 1977, 297(September (13)):686-691.
53. Specter S., Schuermann L., Hakiruwizera C., Sow M.S. ASM LabCap's contributions to disease surveillance and the International Health Regulations. BMC Public Health 2005, (10 Suppl. 1):S7.